For the first quarter ended June 30, 2015, Zydus Cadila reported total operating income of
Rs. 2,500 crore, up by 22% from Rs. 2,050 crore in the corresponding quarter of the previous year on a consolidated basis. The net profit is up by 47% to Rs. 353 crore from Rs. 240 crore in the first quarter of 2014-15.
The company's formulations business in the US grew by 37%. During the quarter, the group filed 6 additional ANDAs with the USFDA and launched one new product in the US.
In the Indian formulations market, the company launched 12 new products, including line extensions, of which 4 products were the first to be launched in India.
Taking its breakthrough therapy, Lipaglyn (Saroglitazar) to global forums, the group presented new clinical data on Lipaglyn at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress at Nashville, Tennessee, USA and at the 75th Annual Scientific Sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, USA, during the quarter.
The Board has approved the proposal to sub-divide existing equity shares of face value Rs. 5/- each into 5 equity shares of face value Re. 1/- each, subject to requisite approvals.